Teplizumab Now Approved to Delay Type 1 Diabetes in Young Children—Here's What You Need to Know

Teplizumab (brand name Tzield) is a humanized monoclonal antibody—a type of immune-modifying medication. It works by binding to a molecule called CD3 on T lymphocytes, immune cells that mistakenly attack the insulin-producing beta cells in the pancreas during type 1 diabetes.

Rather than stopping the immune system entirely, teplizumab partially resets it. It promotes exhaustion of the beta-cell-attacking CD8+ T lymphocytes and encourages the growth of regulatory T lymphocytes, which help restore self-tolerance. In other words, it teaches the immune system to stop attacking the pancreas.

In November 2022, teplizumab became the first drug approved by the FDA to delay the onset of stage 3 type 1 diabetes in adults and children age 8 and older who have stage 2 disease. In April 2026, it was approved for young children, expanding access to this disease-modifying therapy.

In a phase 3 clinical trial, children and adolescents who received teplizumab had significantly higher stimulated C-peptide levels—a measure of insulin production—at week 78 compared to those who received placebo. Nearly 95% of teplizumab-treated patients maintained a clinically meaningful C-peptide level, compared to about 79% of placebo recipients.

An integrated analysis combining data from five clinical trials involving 609 patients confirmed these findings. One year after teplizumab treatment, patients showed an average increase in C-peptide levels, and by year 2, the improvement was even greater. This indicates teplizumab helps preserve the body's natural ability to make insulin over time.

The trials also found that patients treated with teplizumab required lower daily insulin doses to manage their blood sugar compared to the placebo group. However, the groups did not differ significantly on other key measures like hemoglobin A1C levels, time in target glucose range, or hypoglycemic events—suggesting that while beta-cell function is preserved, other aspects of disease management remain important.

Teplizumab is approved in the US for people age 1 and older who have stage 2 type 1 diabetes. The original 2022 approval covered ages 8 and up; in April 2026 the FDA expanded the indication down to age 1 based on the PETITE-T1D study. Stage 2 is an early phase of the disease characterized by dysglycemia—abnormal blood sugar levels—but without the clinical symptoms and insulin dependence of stage 3.

The drug is administered as two separate 12-day courses of intravenous infusions. This means identifying people in stage 2 is critical, which is why screening for type 1 diabetes autoantibodies and early glucose abnormalities is expanding globally. People with a family history of type 1 diabetes, or those identified through screening programs, may be candidates for treatment before symptoms appear.

Currently recruiting clinical trials are evaluating teplizumab in Japanese participants and gathering long-term follow-up data in stage 2 patients treated in real-world settings, broadening the evidence base for its use.

In clinical trials involving approximately 1,500 patient-years of follow-up, the most common adverse events were lymphopenia (low white blood cell counts), rash, and headache. The vast majority of these side effects occurred during and shortly after the first few weeks of teplizumab administration.

Importantly, most adverse events resolved without additional intervention. The safety profile has been consistent across multiple trials in people with both stage 2 and stage 3 disease. As always, discuss potential risks and benefits with your healthcare team to determine if teplizumab is appropriate for your situation.

For over a century, insulin has been the cornerstone of type 1 diabetes treatment—a life-saving symptomatic therapy. Teplizumab represents a shift toward disease-modifying treatment, one that slows the underlying autoimmune attack rather than simply managing its consequences.

Teplizumab delays progression from stage 2 to stage 3 by approximately 3 years on average. This is not a cure, but it is a meaningful opportunity to extend the period before insulin dependence begins and to help preserve some natural insulin production capacity.

The expansion of screening efforts and regulatory approval in young children means more families have the opportunity to identify type 1 diabetes early and explore this option before symptoms develop. This ushers in a new era where disease modification—not just symptom management—can become part of standard care.

Origin: WebWire (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.